Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease | Zendy

Nan Ye | Zendy; Meg Jardine | Zendy; Megumi Oshima | Zendy; Carinna Hockham | Zendy; Hiddo J.L. Heerspink | Zendy; Rajiv Agarwal | Zendy; George L. Bakris | Zendy; Aletta E. Schutte | Zendy; Clare Arnott | Zendy; Tara I. Chang | Zendy; José Luis Górriz | Zendy; Christopher P. Can | Zendy; David M. Charytan | Zendy; Dick de Zeeuw | Zendy; Adeera Levin | Zendy; Kenneth W. Mahaffey | Zendy; Bruce Neal | Zendy; Carol A. Pollock | Zendy; David C. Wheeler | Zendy; Gian Luca Di Tanna | Zendy; Hong Cheng | Zendy; Vlado Perkovic | Zendy; Brendon L. Neuen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease

Author(s) -

Nan Ye,

Meg Jardine,

Megumi Oshima,

Carinna Hockham,

Hiddo J.L. Heerspink,

Rajiv Agarwal,

George L. Bakris,

Aletta E. Schutte,

Clare Arnott,

Tara I. Chang,

José Luis Górriz,

Christopher P. Can,

David M. Charytan,

Dick de Zeeuw,

Adeera Levin,

Kenneth W. Mahaffey,

Bruce Neal,

Carol A. Pollock,

David C. Wheeler,

Gian Luca Di Tanna,

Hong Cheng,

Vlado Perkovic,

Brendon L. Neuen

Publication year - 2021

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.048740

Subject(s) - canagliflozin , medicine , kidney disease , blood pressure , diabetes mellitus , type 2 diabetes , hazard ratio , empagliflozin , placebo , population , diuretic , endocrinology , confidence interval , pathology , alternative medicine , environmental health

People with type 2 diabetes and chronic kidney disease experience a high burden of hypertension, but the magnitude and consistency of blood pressure (BP) lowering with canagliflozin in this population are uncertain. Whether the effects of canagliflozin on kidney and cardiovascular outcomes vary by baseline BP or BP-lowering therapy is also unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research